Results for tag: "Evista"

Evista (raloxifene) is a selective estrogen receptor modulator (SERM) used to treat and prevent osteoporosis in postmenopausal women. It is also used to reduce the risk of invasive breast cancer in postmenopausal women who have osteoporosis or who are otherwise at risk for the disease. Evista is the only SERM approved for both the prevention and treatment of breast cancer. Evista is part of a larger market of breast cancer drugs, which includes hormone therapy, chemotherapy, targeted therapy, and immunotherapy. Hormone therapy is used to block the effects of hormones like estrogen, which can fuel the growth of certain types of breast cancer. Chemotherapy is used to kill cancer cells, while targeted therapy and immunotherapy are used to target specific cancer cells and boost the body's immune system, respectively. The Evista market is composed of several companies, including Eli Lilly, Pfizer, Novartis, and AstraZeneca. Show Less Read more